Alnylam suspends bleeding disorder trial dosing after patient death

(Reuters) - U.S. drug developer Alnylam Pharmaceuticals Inc said on Thursday it stopped giving doses of its experimental drug for a rare bleeding disorder to patients enrolled in its clinical studies following a patient's death.

Source: Reuters: Health - September 7, 2017 Category: Consumer Health News Tags: healthNews Source Type: news